2018, Number 3
<< Back Next >>
Rev Hematol Mex 2018; 19 (3)
Public and private hematology: Differences and similarities among patients of first time consultation
Solano-Herrejón KY, Gómez-De León A, González-López EE, Ríos-González LI, López-Garza MI, Gómez-Almaguer D
Language: Spanish
References: 16
Page: 115-122
PDF size: 253.05 Kb.
ABSTRACT
Background: There is an important division in the distribution of income and health
services access in countries with limited resources.
Objective: To determine and to compare some characteristics of patients with hematological
diseases of the public sector assisting to the first time consultation, contrasting
them with those of the patients assisting to the private sector.
Material and Method: A retrospective observational study was performed, where
we describe the clinical and epidemiological characteristics of patients in the public
sector with available services corresponding to the National Health Ministry in a reference
hospital in northeastern Mexico and compare them to patients from a private
consult on the same geographic area during 2014-2015.
Results: Seven hundred and ninety-three patients were included, 49.7% from the
public sector. Diagnostic consults were more common in the public sector (p ‹ 0.001),
in contrast to therapeutic or second opinion consults (p ‹ 0.05). The most common
reason for consult was anemia in both sectors. Patients in the public sector were older,
and had a higher proportion neoplastic disease, with lower hemoglobin levels. In the
private sector, there were more consults for a second opinion, and benign disorders.
Conclusions: The patient profile of the private sector system includes more patients
with anemia than the public sector. The most common diseases in the public sector
are of a neoplastic nature, especially lymphomas.
REFERENCES
Gómez-Dantés O, Sesma S, Becerril-Montekio V, et al. Sistema de salud de México. Salud Púb Méx 2011;Sup2 S220-S232.
GLOBOCAN Fact sheets by population (nd) Accesado Diciembre 2014, 2015 de http://globocan.iarc.fr/Page/ fact_sheets_population.aspx
Meneses-García A. Principales neoplasias malignas en México y su distribución geográfica (1993-2002). Rev Invest Clín 2012;64:322-29.
Fernández CS, León AG, Herrera TM, et al. Perfil epidemiológico de los tumores malignos en México. Secretaría de salud 2011. Revisado el 8 de febrero 2018 https:// epidemiologiatlax.files.wordpress.com/2012/10/p_epi_ de_los_tumores_malignos_mc3a9xico.pdf
Reynoso-Noverón N, Mohar A. El cáncer en México: propuestas para su control. Salud Púb Méx 2014;56:418-20.
Wright D, Smith G, Norfolk D, et al. Sources and types of referral to a hematology department. Health Trends 1992;24:145-8.
Nassur R, Mangel J, Chin-Yee I. Delays in the cancer pathway from symptom onset to initiation of treatment – A retrospective study in patients with non Hodgkin’s lymphoma. Blood 2015;108:347.
Allgar VL, Neal RD. Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS patients: cancer. Br J Cancer 2005;92:1959-70.
Prevención, diagnóstico y tratamiento de la anemia por deficiencia de hierro en niños y adultos. Secretaría de Salud 2010. www.cenetec.salud.gob.mx/interior/gpc.html Revisado el 8 de febrero 2018.
Pasricha SR, Colman K, Centeno-Tablante E, et al. Revisiting WHO haemoglobin thresholds to define anemia in clinical medicine and public health. Lancet Haematol 2018;5(2):e60-e62.
Njuguna F, Martijn H, Langat S, et al. Factors influencing time to diagnosis and treatment among pediatric oncology patients in Kenya. Pediatr Hematol Oncol 2016;33:186-99.
Ambroggi M, Biasini C, Del Giovane C, et al. Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist 2015;20:1378-85.
Nikonova A, Guirguis HR, Buckstein R, et al. Predictors of delay in diagnosis and treatment in diffuse large Bcell lymphoma and impact on survival. Br J Haematol 2015;168:492-500.
Obtel M, Berraho M, Abda N, et al. Factors associated with delayed diagnosis of lymphomas: experience with patients from hematology centers in Morocco. Asian Pac J Cancer Prev 2017;18:1603-1610.
Venkatasai JP Srinivasamaharaj S, Sneha LM, et al. Pediatric hematological malignancy: identification of issues involved in the road to diagnosis. South Asian J Cancer 2017;6:28-30.
Tarín-Arzaga L, Arredondo-Campos, D, Martínez-Pacheco V, et al. Impact of the affordability of novel agents in patients with multiple myeloma. Real-world data of current clinical practice in Mexico. Cancer 2018 Feb 20. Doi 10.1002/ cncr.31305